News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Streamex raised over $40 million, fully deleveraged its balance sheet, and launched GLDY, per Q1 2026 results.
  • Trump and Xi concluded a state visit after talks that signaled a trade truce and possible large Chinese purchases of U.S. goods.
  • Xi warned missteps over Taiwan could push U.S.-China ties into "a very dangerous place," raising geopolitical risk.
  • The Pentagon canceled a planned temporary deployment of 4,000 U.S. troops to Poland, prompting questions about U.S. force posture in Europe.
  • FEMSA's NetPay launched a digital payments platform for Mexican gas stations to accept card, QR-code and CoDi transactions.
  • Cavco Industries scheduled its fiscal Q4 and year-end earnings release for May 21 with a webcast and call on May 22.

Latest Articles

MSCI Posts Higher Q4 Profit as Clients Flock to Indexes and Analytics

MSCI Posts Higher Q4 Profit as Clients Flock to Indexes and Analytics

MSCI reported stronger adjusted profit for the quarter ended December 31, driven by increased client spending on its index products and analytics services. Asset-based fees rose, lifting overall revenue, while operating costs grew more modestly as the company invested in staff and technology. Management highlighted continued multi-year growth in ad…

Mastercard at $520: An Oversold Reset With Earnings as the Next Spark

Mastercard at $520: An Oversold Reset With Earnings as the Next Spark

Mastercard (MA) has pulled back to roughly $522 after a sharp slide from the $600s, leaving the stock oversold (RSI ~29.9) and well below its 20- and 50-day averages. With earnings due 01/29/2026 and consumer spending described as holding firm in recent coverage, MA sets up as a tactical long: defined risk below recent lows and upside toward the fi…

Wix Board Greenlights $2 Billion Buyback; Shares Jump on Announcement

Wix Board Greenlights $2 Billion Buyback; Shares Jump on Announcement

Wix.com Ltd. shares rose sharply after the company’s board approved a $2 billion share repurchase program spanning fiscal years 2026-2027. The authorization permits purchases of ordinary shares and convertible notes via open market and private transactions, to be funded by cash on hand, operating cash flow, or potentially new capital. The program i…

Eviction Orders Increase in Silwan as Settler Group Expands Hold in East Jerusalem

Eviction Orders Increase in Silwan as Settler Group Expands Hold in East Jerusalem

Residents of Silwan in East Jerusalem report receiving eviction orders that favor Ateret Cohanim, a settler organization that has acquired dozens of properties in the district. Dozens of families have been told to leave under a Supreme Court order, with deadlines tied to the end of Ramadan - mid-March - while tensions over settlement activity and a…

Birkenstock Seeks €1 Billion in New Revenue Over Next Three Years

Birkenstock Seeks €1 Billion in New Revenue Over Next Three Years

Birkenstock has set a target of generating 1 billion euros in incremental revenue across the next three years, aiming for annual top-line growth of 13%-15% at constant currencies. The company expects double-digit expansion in the Americas and EMEA, a doubling of its Asia-Pacific business, and adjusted EPS to grow about 200 basis points faster than …

BMO Lifts Stride Price Target to $94, Keeps Market Perform Rating

BMO Lifts Stride Price Target to $94, Keeps Market Perform Rating

BMO Capital raised its price objective on Stride Inc. (NYSE: LRN) to $94 from $75 while retaining a Market Perform rating, citing fiscal second-quarter 2026 results that beat expectations largely due to a one-time gain. Management reaffirmed full-year revenue guidance and raised adjusted operating income expectations, even as core General Education…

Trump Demands Iran Return to Negotiating Table or Face 'Far Worse' Strike

Trump Demands Iran Return to Negotiating Table or Face 'Far Worse' Strike

President Donald Trump issued a public ultimatum urging Iran to negotiate a nuclear deal or face a more severe U.S. military response, writing that time is running out and calling for an agreement with "NO NUCLEAR WEAPONS." He said the previous warning led to a strike and warned that the next attack would be "far worse," while also asserting that a…

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS cut its rating on Swiss property owner Mobimo to sell from neutral, saying the company’s development profits - a key earnings driver - should peak in fiscal 2025 and then decline as high-margin projects complete. The broker raised its 12-month price target to CHF330 from CHF308 after lowering its WACC and modestly raising revenue forecasts, but…

F5 Networks Holds Course After Strong Q1; Needham Sticks With Hold Rating

F5 Networks Holds Course After Strong Q1; Needham Sticks With Hold Rating

F5 Networks reported first-quarter fiscal 2026 results that outperformed expectations, prompting an upward revision to full-year guidance while leaving some analysts cautious. The company beat revenue and EPS forecasts, posted strong margins and notable regional and segment gains, yet Needham preserved a Hold rating pending more sustained outperfor…

H.C. Wainwright Sticks With Buy on Maze Therapeutics, Keeps $60 Target Citing Regulatory Pathway Tailwind

H.C. Wainwright Sticks With Buy on Maze Therapeutics, Keeps $60 Target Citing Regulatory Pathway Tailwind

H.C. Wainwright reaffirmed its Buy rating and $60 price target for Maze Therapeutics (MAZE), citing a potential regulatory shortcut enabled by pediatric extrapolation for APOL1-mediated kidney disease. Multiple analysts have adjusted models and initiated coverage over recent weeks, reflecting heightened optimism ahead of a pivotal Phase 2 HORIZON r…